Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002962 (angina)
 21,142 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A double-blind placebo controlled study of angina pectoris with penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.
 ...
PMID:A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris. 1 57

Results with a new anti-angina molecule (nifedipine: Adalat) in the long-term management of 28 patients with ischaemic heart disease are presented. The effectiveness of the drug was judged outstanding on the strength of its reduction of angina outstanding on the strength of its reduction of angina crises and consumption of NTG beads. Non side-effects were noted.
 ...
PMID:[Long-term clinical study of a new molecule (nifedipine) in ischemic cardiopathy]. 40 86

3 patients with different clinical and electrocardiographic manifestations of coronary artery spasm are discussed. All 3 patients had anginal attacks at rest. In addition, 2 of these patients, who did not have significant preexisting narrowing of their coronary arteries, also had anginal pain related to exercise. During pain, 1 patient showed ST-segment elevation, the other ST-segment depression, while the third showed ST-segment depression shortly followed by ST-elevation on the electrocardiogram. At coronary angiography, spontaneous or induced spasm of one of the major coronary arteries could be demonstrated in all 3 patients. In 2 cases, sublingual nitroglycerin failed to completely relieve the spasm. This raises the question whether a residual stenosis after NTG conclusively proves a fixed organic narrowing. It is concluded that the clinical spectrum of spasm of the coronary arteries is wider than was originally reported by Prinzmetal and coworkers. Clinical and electrocardiographic manifestations are probably dependent on the site and severity of the spasm, which may cause different degrees of myocardial ischemia.
 ...
PMID:Variant forms of angina pectoris. 71 Apr 90

Isosorbide dinitrate was given orally to 6 patients with anginal pain on exertion and its effect on exercise capacity, ECG and other hemodynamic parameters was compared with the control values and with the results of a group of 6 patients who received a placebo. The drug seems to affect favourably the working capacity and the ECG on exercise for a longer period than NTG while we do not observe a placebo effect.
 ...
PMID:Clinical and circulatory effects of oral isosorbide dinitrate in patients with angina during exercise. 108 59

This study compared glycerol trinitrate (NTG) oral spray in a new hydrophilic formulation with a reference aerosol in a lipophilic base with respect to the time to onset of action on hemodynamics and on the coronary vasomotor tone. Differences in the profile of action between the two spray formulations were assessed in two groups of ten patients each. In each of the two groups the patients were randomly assigned to receive 0.8 mg of aerosolized NTG in either the hydrophilic or lipophilic base in double-blind fashion. The patients of group A had stable, exercise-induced angina pectoris, in whom responses to the sprays were evaluated under resting conditions. The patients of group B were suspicious of vasospastic or mixed form of angina pectoris, in whom the effects of the sprays were studied under diagnostic ergonovine provocation. The onset and extent of action of the sprays were assessed by serial measurements of hemodynamic parameters and repeat quantitative coronary angiography. The two formulations of NTG oral spray had a comparably potent coronary vasodilator effect in patients under resting conditions and under ergonovine provocation. As far as hemodynamic action is concerned, the new hydrophilic spray exerted its hemodynamic effect more rapidly than the lipophilic spray. Thus, the new NTG oral spray promises to afford therapeutic advantages for the relief of anginal attacks as well as hemodynamic unloading in congestive heart failure and acute pulmonary hypertension.
 ...
PMID:Hemodynamic and coronary vasodilative action of two nitroglycerin oral spray formulations. 212 41

Two cases of perioperative coronary spasm following ASD closure and OMC are reported. A 36-year-old female had been diagnosed of vasospastic angina and another 47-year-old female patient was diagnosed of effort angina for 99% stenosis of the right ventricular branch preoperatively. Both patients suffered from coronary vasospastic attack and ventricular fibrillation several times within 17 hours postoperatively. Although the coronary dissolution was obtained finally following aggressive cardiac massage, administration of spasmolytic agents, such as NTG, lidocaine, DBcAMP and the start of IABP, the resolution was stormy due to the hemodynamic derangement. To prevent the coronary spastic episode, it is suggested, for patients of possible coronary spasm, to avoid arousal stimulation and to administer spasmolytic agents prophylactically within the first postoperative day.
 ...
PMID:[Two cases of perioperative coronary vasospasm following ASD closure and OMC]. 225 Apr 35

The transdermal nitroglycerin patches have been very successful nitrate formulations since their introduction in 1982. Nevertheless, considerable controversy regarding efficacy and tolerance has arisen. Nitroglycerin has multiple mechanisms of action in angina pectoris. Transdermal nitroglycerin in ointment formulation has been known to be effective in angina. The patches, when used in a dose of greater than or equal to 10 mg (24 h)-1, provide classic nitrate NTG effects in angina patients. However, the problem of nitrate tolerance is significant; in acute dosing, the transdermal patches lose their efficacy by 24 h and, with chronic dosing, appear usually to have little advantage over placebo in improvement of angina. An intermittent or interval approach to transdermal patch delivery appears to be the best method of avoiding nitrate tolerance. Current data suggest using the patches for 12 or 14 h consecutively and then removing them for 10-12 h. Such dosing strategies appear to eliminate or markedly reduce the problem of nitrate tolerance.
 ...
PMID:Transdermal nitroglycerin in angina pectoris. 250 Oct 90

The effects of i.v. nitroglycerin were studied by ECG and enzymatically in 16 patients (mean age 57.9 +/- 1.4 years) (NTG) in comparison with a control lot (c) of 17 patients (mean age 62.7 +/- 2.1 years) treated with dipyridamole and/or nifedipine (N), admitted in the first 4-10 hours after the onset of the first symptoms. The patients with heart failure and those with Q waves and CPK or LDH values greater than 2 x n were not admitted. NTG was administered in doses of 20 micrograms--60 microgram/hour for 24-96 hours and systolic AT (s) was kept under 10% of the basic values but not under 100 mmHg. Myocardial infarction appeared in 9 N-treated patients (54.86%) and 11 controls (58.25%) (p = 0.07). The size of myocardial necrosis was reduced in the N-treated patients. Peak serum CPK levels had considerably less increases in N (from 72.9 U to 73.4 U) (p greater than 00.5) versus C from 34.2 U to 364.5 U) (p less than 0.001). The sum of segmentary depression failed from 9.13 mm to 3.19 mm (p less than 0.05) in N, whereas in C the decrease was not significant (6.12 mm as against 9.38 mm; p greater than 0.05). The evolution was severe in C, as the angina crises (14 cases versus 2 cases, p less than 0.01) and the extension of the infarction (8 cases versus, 0; p 0.05) less than 0.05) appeared more frequently than in N. Only two patients in C died (p less than 0.05). Therefore, i.v. NTG administration in small doses in acute myocardial infarction leads to immediate disappearance of the anginal pain, lowers the extent of the myocardial necrosis and improves the clinical evolution.
 ...
PMID:[The effects of nitroglycerin administered intravenously in acute myocardial ischemia]. 257 23

This is the first reported large clinical trial of the antianginal and acute ischemic effectiveness and safety of dilevalol (the R, R-isomer of labetalol) in patients with chronic stable angina pectoris. This was a multicenter double blind fixed-dose parallel group placebo controlled trial. Patients with chronic stable angina and positive and reproducible exercise tests (+/- 20%) were included. If randomized, patients entered one of four fixed dose groups (twice a day placebo, 100 mgm, 200 mgm and 400 mgm bid for 2 weeks). Exercise testing was performed at 2 hours (peak) and 12 hours (trough) postdosing. This was followed by a 2-week once-a-day dosing regimen in which patients received the same total daily dose as the prior 2 weeks, with the full dose in the morning and a matched placebo in the evening. Exercise testing was performed at 2 hours (peak) and 24 hours (trough) postdosing. Anginal frequency and NTG consumption were significantly reduced, and equally so, by qd and bid regimens. The time of exercise to the onset of angina increased and the proportion of patients terminating exercise because of moderate angina decreased in a dose response fashion for both peak and trough tests and for both qd and bid regimens. There was also a dose related decrease in exercise induced ST segment depression and an increase in time to 1 mm ST depression. In 15 patients, 24-hour ambulatory monitoring also revealed a decrease in episodes of silent ischemia. No significant side effects related to the study drug occurred.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The efficacy and safety of dilevalol in patients with chronic stable angina pectoris. 257 29

The antiischemic effects of the beta-1 selective beta-blocker metoprolol were studied in 9 hospitalized patients with rest angina in a double-blind, placebo-controlled, cross-over study. After 3 days of placebo treatment, the patients were randomized to metoprolol 100 mg or placebo bid for 2 days, followed by 2 days on the alternative treatment. During the last 24 hours of each period, Holter monitoring was performed. The patients marked angina attacks and NTG consumption on diary cards. Metoprolol significantly reduced the mean number of ST-changes (run-in: 5.7 +/- 0.6; metoprolol: 2.2 +/- 0.9; p = 0.013), the mean maximal ST-change during the attacks (run-in: 3.0 +/- 1.2 mm; metoprolol: 1.5 +/- 0.4 mm; p = 0.015), the mean duration of the ST-changes (run-in: 7.0 +/- 0.6 min; metoprolol: 3.2 +/- 1.0 min; p = 0.015), and the total ischemic time/24 (run-in: 41.1 +/- 7.6; metoprolol: 13.1 +/- 7.2 min; p = 0.008). None of these parameters was modified by placebo. However, the difference between metoprolol and the randomized placebo did not reach statistical significance. Metoprolol also reduced the number of chest pain attacks (p = 0.008), the duration of the attacks (p = 0.051), the severity score of the attacks (p = 0.008), and NTG consumption (p = 0.018) with respect to the run-in period. Six of the patients showed marked improvement on metoprolol while 3 showed only slight improvement or no change. No patients experienced worsening of angina or ST-changes.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Cardioselective beta-blockade with metoprolol in rest angina: a randomized, double-blind, placebo-controlled, cross-over trial. 266 58


1 2 3 Next >>